ADRB2 Arg16Gly polymorphism, lung function, and mortality: Results from the atherosclerosis risk in communities study

PLoS ONE

Volumn 2, Issue 3, 2007, Pages

  Ferdinands, Jill M ^a   Mannino, David M ^b   Gwinn, Marta L ^c   Bray, Molly S ^d  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; GLYCINE; STEROID; THEOPHYLLINE;

ADULT; ARTICLE; ASTHMA; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; FORCED EXPIRATORY VOLUME; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OVERALL SURVIVAL; RACE DIFFERENCE; SMOKING HABIT; SURVIVAL RATE; AMINO ACID SUBSTITUTION; COHORT ANALYSIS; FOLLOW UP; GENETIC POLYMORPHISM; GENETICS; LUNG; LUNG FUNCTION TEST; MIDDLE AGED; MISSENSE MUTATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROBABILITY; RISK FACTOR; SMOKING; UNITED STATES;

AMINO ACID SUBSTITUTION; ATHEROSCLEROSIS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; PROBABILITY; RECEPTORS, ADRENERGIC, BETA-2; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SMOKING; UNITED STATES;

EID: 34548747281     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0000289     Document Type: Article

References (34)

1. Mannino DM, Homa DM, Akinbami LJ, Moorman JE, Gwynn C, et al. (2002) Surveillance for asthma-United States, 1980-1999. MMWR Surveill Summ 51: 1-13.
2. Ortega AN, Gergen PJ, Paltiel AD, Bauchner H, Belanger KD, et al. (2002) Impact of site of care, race, and Hispanic ethnicity on medication use for childhood asthma. Pediatrics 109: E1.
3. Sears MR, Taylor DR (1994) The beta 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 11: 259-283.
4. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, et al. (1992) The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506.
5. Mullen M, Mullen B, Carey M (1993) The association between beta-agonist use and death from asthma. A meta-analytic integration of case-control studies. JAMA 270: 1842-1845.
6. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129: 15-26.
7. Johnson M (1998) The beta-adrenoceptor. Am J Respir Crit Care Med 158: S146-S153.
8. Joos L, Sandford AJ (2002) Genotype predictors of response to asthma medications. Curr Opin Pulm Med 8: 9-15.
9. Raby BA, Weiss ST (2001) Beta2-adrenergic receptor genetics. Curr Opin Mol Ther 3: 554-566.
10. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, et al. (2004) Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 364: 1505-1512.
11. Turner SW, Khoo SK, Laing IA, Palmer LJ, Gibson NA, et al. (2004) beta2 adrenoceptor Arg16Gly polymorphism, airway responsiveness, lung function and asthma in infants and children. Clin Exp Allergy 34: 1043-1048.
12. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, et al. (2000) The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162: 75-80.
13. Summerhill E, Leavitt SA, Gidley H, Parry R, Solway J, et al. (2000) beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 162: 599-602.
14. Taylor DR, Hancox RJ, McRae W, Cowan JO, Flannery EM, et al. (2000) The influence of polymorphism at position 16 of the beta2-adrenoceptor on the development of tolerance to beta-agonist. J Asthma 37: 691-700.
15. Ramsay CE, Hayden CM, Tiller KJ, Burton PR, Goldblatt J, et al. (1999) Polymorphisms in the beta2-adrenoreceptor gene are associated with decreased airway responsiveness. Clin Exp Allergy 29: 1195-1203.
16. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997) Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100: 3184-3188.
17. Taylor M (2006) Pharmacogenetics of the human beta-adrenergic receptors. The Pharmacogenomics Journal 2006: 1-9.
18. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, et al. (2006) Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J.
19. Tantisira KG, Weiss ST (2005) The pharmacogenetics of asthma: an update. Curr Opin Mol Ther 7: 209-217.
20. Wechsler ME, Israel E (2005) How pharmacogenomics will play a role in the management of asthma. Am J Respir Crit Care Med 172: 12-18.
21. Israel E (2005) Genetics and the variability of treatment response in asthma. J Allergy Clin Immunol 115: S532-S538.
22. Thakkinstian A, McEvoy M, Minelli C, Gibson P, Hancox B, et al. (2005) Systematic review and meta-analysis of the association between {beta}2-adrenoce- ptor polymorphisms and asthma: a HuGE review. Am J Epidemiol 162: 201-211.
23. Contopoulos-Ioannidis DG, Manoli EN, Ioannidis JP (2005) Meta-analysis of the association of beta2-adrenergic receptor polymorphisms with asthma phenotypes. J Allergy Clin Immunol 115: 963-972.
24. The Atherosclerosis Risk in Communities (ARIC) (1989) Study: design and objectives. The ARIC investigators. Am J Epidemiol 129: 687-702.
25. Hankinson JL, Odencrantz JR, Fedan KB (1999) Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 159: 179-187.
26. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summary. Am J Respir Crit Care Med 163: 1256-1276.
27. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 158: 1855-1867.
28. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, et al. (2000) Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 55: 762-767.
29. Busse WW, Rosenwasser LJ (2003) Mechanisms of asthma. J Allergy Clin Immunol 111: S799-S804.
30. International HapMap Project; http://www.HapMap.org, accessed January 28, 2007.
31. Belfer I, Buzas B, Evans C, Hipp H, Phillips G, et al. (2005) Haplotype structure of the beta adrenergic receptor genes in US Caucasians and African Americans. Eur J Hum Genet 13: 341-351.
32. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, et al. (2006) Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 174: 1101-1109.
33. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R (1997) Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 100: 3184-3188.
34. Dewar JC, Wheatley AP, Venn A, Morrison JF, Britton J, et al. (1998) Beta2- adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population. Clin Exp Allergy 28: 442-448.